Affordable Access

Access to the full text

Immune-Based Approaches for the Treatment of Pediatric Malignancies

Authors
  • Bosse, Kristopher R.
  • Majzner, Robbie G.
  • Mackall, Crystal L.
  • Maris, John M.
Type
Published Article
Journal
Annual Review of Cancer Biology
Publisher
Annual Reviews
Publication Date
Mar 04, 2020
Volume
4
Pages
353–370
Identifiers
DOI: 10.1146/annurev-cancerbio-030419-033436
Source
Annual Reviews
Keywords
License
Green

Abstract

Immune-based therapies have now been credentialed for pediatric cancers with the robust efficacy of chimeric antigen receptor (CAR) T cells for pediatric B cell acute lymphocytic leukemia (ALL), offering a chance of a cure for children with previously lethal disease and a potentially more targeted therapy to limit treatment-related morbidities. The developmental origins of most pediatric cancers make them ideal targets for immune-based therapies that capitalize on the differential expression of lineage-specific cell surface molecules such as antibodies, antibody-drug conjugates, or CAR T cells, while the efficacy of other therapies that depend on tumor immunogenicity such as immune checkpoint inhibitors has been limited to date. Here we review the current status of immune-based therapies for childhood cancers, discuss challenges to developing immunotherapeutics for these diseases, and outline future directions of pediatric immunotherapy discovery and development.

Report this publication

Statistics

Seen <100 times